Top news of the week: 15.04.2021.
Companies And Industries
2021 COVID-19 News: Breakthrough Cases, Children's Viral Load and More
Please check out the biopharma industry's COVID-19 stories that are trending for April 13, 2021.
COVID-19 Brief: Theories on the COVID-19 Blood Clotting and More Top Stories
The top COVID-19 story is on the pause of the Johnson & Johnson vaccine in the U.S. over rare blood clots. But it’s not the only news. Here’s a look.
Sanofi pays $160M for mRNA tech to reprogram T cells in vivo
Sanofi has paid $160 million upfront to buy a preclinical biotech that is using mRNA to reprogram immune cells inside the human body. The technology could enable patients to make their own ...
New CUT&Tag Approach Profiles Chromatin Modifications in Single Cells
A new method, single-cell CUT&Tag, gives an unbiased view of complex tissues with high resolution by examining epigenetic information in single cells.
Clinical Catch-Up: April 5-9
It was a relatively quiet week for clinical trial announcements, but there were a few standouts. Read on for more.
Fraudsters Posing as Biotech Companies Seek to Capitalize on COVID-19 Panic
The fear caused by COVID-19 provides an “in” for fraudsters to exploit thousands of Americans by posing as biotech companies.
New name, new board, new focus: AltruBio relaunches with $63M series A
AltruBio would like to reintroduce itself. After shifting from oncology to immunology, swapping out the board and completing a name change, the biotech is relaunching with a $63 million ...
COVID player and Pfizer-partnered Valneva eyes $100M Nasdaq IPO
French biotech Valneva, which has developed a lineup of traveler vaccines and is starting a late-stage COVID vax effort, is seeking to level up to the Nasdaq with a $100 million IPO.